Affordable Access

Antioxidants as potential therapeutics for lung fibrosis.

Authors
  • Day, Brian J
Type
Published Article
Journal
Antioxidants and Redox Signaling
Publisher
Mary Ann Liebert
Publication Date
Feb 01, 2008
Volume
10
Issue
2
Pages
355–370
Identifiers
PMID: 17999627
Source
Medline
License
Unknown

Abstract

Interstitial lung disease encompasses a large group of chronic lung disorders associated with excessive tissue remodeling, scarring, and fibrosis. The evidence of a redox imbalance in lung fibrosis is substantial, and the rationale for testing antioxidants as potential new therapeutics for lung fibrosis is appealing. Current animal models of lung fibrosis have clear involvement of ROS in their pathogenesis. New classes of antioxidant agents divided into catalytic antioxidant mimetics and antioxidant scavengers are being developed. The catalytic antioxidant class is based on endogenous antioxidant enzymes and includes the manganese-containing macrocyclics, porphyrins, salens, and the non-metal-containing nitroxides. The antioxidant scavenging class is based on endogenous antioxidant molecules and includes the vitamin E analogues, thiols, lazaroids, and polyphenolic agents. Numerous studies have shown oxidative stress to be associated with many interstitial lung diseases and that these agents are effective in attenuating fibroproliferative responses in the lung of animals and humans.

Report this publication

Statistics

Seen <100 times